210 related articles for article (PubMed ID: 34766133)
1. Roles of hepatic atypical protein kinase C hyperactivity and hyperinsulinemia in insulin-resistant forms of obesity and type 2 diabetes mellitus.
Sajan MP; Hansen BC; Acevedo-Duncan M; Kindy MS; Cooper DR; Farese RV
MedComm (2020); 2021 Mar; 2(1):3-16. PubMed ID: 34766133
[TBL] [Abstract][Full Text] [Related]
2. Hepatic insulin resistance in ob/ob mice involves increases in ceramide, aPKC activity, and selective impairment of Akt-dependent FoxO1 phosphorylation.
Sajan MP; Ivey RA; Lee MC; Farese RV
J Lipid Res; 2015 Jan; 56(1):70-80. PubMed ID: 25395359
[TBL] [Abstract][Full Text] [Related]
3. Correction of metabolic abnormalities in a rodent model of obesity, metabolic syndrome, and type 2 diabetes mellitus by inhibitors of hepatic protein kinase C-ι.
Sajan MP; Nimal S; Mastorides S; Acevedo-Duncan M; Kahn CR; Fields AP; Braun U; Leitges M; Farese RV
Metabolism; 2012 Apr; 61(4):459-69. PubMed ID: 22225955
[TBL] [Abstract][Full Text] [Related]
4. Atypical protein kinase C in cardiometabolic abnormalities.
Farese RV; Sajan MP
Curr Opin Lipidol; 2012 Jun; 23(3):175-181. PubMed ID: 22449812
[TBL] [Abstract][Full Text] [Related]
5. Coordinated regulation of hepatic FoxO1, PGC-1α and SREBP-1c facilitates insulin action and resistance.
Sajan MP; Lee MC; Foufelle F; Sajan J; Cleland C; Farese RV
Cell Signal; 2018 Mar; 43():62-70. PubMed ID: 29269047
[TBL] [Abstract][Full Text] [Related]
6. BMI-related progression of atypical PKC-dependent aberrations in insulin signaling through IRS-1, Akt, FoxO1 and PGC-1α in livers of obese and type 2 diabetic humans.
Sajan MP; Ivey RA; Farese RV
Metabolism; 2015 Nov; 64(11):1454-65. PubMed ID: 26386696
[TBL] [Abstract][Full Text] [Related]
7. Akt-dependent phosphorylation of hepatic FoxO1 is compartmentalized on a WD40/ProF scaffold and is selectively inhibited by aPKC in early phases of diet-induced obesity.
Sajan MP; Acevedo-Duncan ME; Standaert ML; Ivey RA; Lee M; Farese RV
Diabetes; 2014 Aug; 63(8):2690-701. PubMed ID: 24705403
[TBL] [Abstract][Full Text] [Related]
8. The critical role of atypical protein kinase C in activating hepatic SREBP-1c and NFkappaB in obesity.
Sajan MP; Standaert ML; Nimal S; Varanasi U; Pastoor T; Mastorides S; Braun U; Leitges M; Farese RV
J Lipid Res; 2009 Jun; 50(6):1133-45. PubMed ID: 19202134
[TBL] [Abstract][Full Text] [Related]
9. Insulin-sensitive protein kinases (atypical protein kinase C and protein kinase B/Akt): actions and defects in obesity and type II diabetes.
Farese RV; Sajan MP; Standaert ML
Exp Biol Med (Maywood); 2005 Oct; 230(9):593-605. PubMed ID: 16179727
[TBL] [Abstract][Full Text] [Related]
10. Atypical PKC, PKCλ/ι, activates β-secretase and increases Aβ
Sajan MP; Hansen BC; Higgs MG; Kahn CR; Braun U; Leitges M; Park CR; Diamond DM; Farese RV
Neurobiol Aging; 2018 Jan; 61():225-237. PubMed ID: 29032894
[TBL] [Abstract][Full Text] [Related]
11. Atypical PKC: a target for treating insulin-resistant disorders of obesity, the metabolic syndrome and type 2 diabetes mellitus.
Farese RV; Lee MC; Sajan MP
Expert Opin Ther Targets; 2014 Oct; 18(10):1163-75. PubMed ID: 25213731
[TBL] [Abstract][Full Text] [Related]
12. PKCλ haploinsufficiency prevents diabetes by a mechanism involving alterations in hepatic enzymes.
Sajan MP; Ivey RA; Lee M; Mastorides S; Jurczak MJ; Samuels VT; Shulman GI; Braun U; Leitges M; Farese RV
Mol Endocrinol; 2014 Jul; 28(7):1097-107. PubMed ID: 24877563
[TBL] [Abstract][Full Text] [Related]
13. Metabolic functions of atypical protein kinase C: "good" and "bad" as defined by nutritional status.
Farese RV; Sajan MP
Am J Physiol Endocrinol Metab; 2010 Mar; 298(3):E385-94. PubMed ID: 19996389
[TBL] [Abstract][Full Text] [Related]
14. Metformin action in human hepatocytes: coactivation of atypical protein kinase C alters 5'-AMP-activated protein kinase effects on lipogenic and gluconeogenic enzyme expression.
Sajan MP; Ivey RA; Farese RV
Diabetologia; 2013 Nov; 56(11):2507-16. PubMed ID: 23933835
[TBL] [Abstract][Full Text] [Related]
15. Control of β-Site Amyloid Precursor Protein-Cleaving Enzyme-1 Expression by Protein Kinase C-λ/ι and Nuclear Factor κ-B.
Sajan MP; Leitges M; Park C; Diamond DM; Wu J; Hansen BC; Duncan MA; Apostolatos CA; Apostolatos AH; Kindy M; Farese RV
Curr Alzheimer Res; 2021; 18(12):941-955. PubMed ID: 34951366
[TBL] [Abstract][Full Text] [Related]
16. Muscle-specific knockout of PKC-lambda impairs glucose transport and induces metabolic and diabetic syndromes.
Farese RV; Sajan MP; Yang H; Li P; Mastorides S; Gower WR; Nimal S; Choi CS; Kim S; Shulman GI; Kahn CR; Braun U; Leitges M
J Clin Invest; 2007 Aug; 117(8):2289-301. PubMed ID: 17641777
[TBL] [Abstract][Full Text] [Related]
17. Hepatic Atypical Protein Kinase C: An Inherited Survival-Longevity Gene that Now Fuels Insulin-Resistant Syndromes of Obesity, the Metabolic Syndrome and Type 2 Diabetes Mellitus.
Farese RV; Lee MC; Sajan MP
J Clin Med; 2014 Jul; 3(3):724-40. PubMed ID: 26237474
[TBL] [Abstract][Full Text] [Related]
18. Insulin-induced activation of atypical protein kinase C, but not protein kinase B, is maintained in diabetic (ob/ob and Goto-Kakazaki) liver. Contrasting insulin signaling patterns in liver versus muscle define phenotypes of type 2 diabetic and high fat-induced insulin-resistant states.
Standaert ML; Sajan MP; Miura A; Kanoh Y; Chen HC; Farese RV; Farese RV
J Biol Chem; 2004 Jun; 279(24):24929-34. PubMed ID: 15069067
[TBL] [Abstract][Full Text] [Related]
19. Role of atypical protein kinase C in activation of sterol regulatory element binding protein-1c and nuclear factor kappa B (NFkappaB) in liver of rodents used as a model of diabetes, and relationships to hyperlipidaemia and insulin resistance.
Sajan MP; Standaert ML; Rivas J; Miura A; Kanoh Y; Soto J; Taniguchi CM; Kahn CR; Farese RV
Diabetologia; 2009 Jun; 52(6):1197-207. PubMed ID: 19357831
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
